| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259045c6eba6e2c5d338b84e0a88b571 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate |
2006-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9572ab1ea0b0aae068fa1b83378d7287
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ad3c589817fbabdb7c53a4a4a58d7b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c93f28cb8a7dace43844c966fbd4961f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cadfec2f1fab9f3e6779b0abc1a86a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6746c838d2d1462a2469edcedba63a60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_274e0e437bc4f74148b2ed028c9c8cc0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22dbe88c904a3155f2ba50ba5ccf7093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7761ca660a7bfac16981a19deadebcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90839bdab1b0e9045fbf93afd01d5cb6 |
| publicationDate |
2009-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009048328-A1 |
| titleOfInvention |
Compound Comprising Prodigiosin From Serratia Macescence B-1231 Kctc 0386Bp for Prevention and Treatment of Acute Graft-Versus-Host Disease |
| abstract |
This invention relates to a composition for the prevention and treatment of acute graft-versus-host disease comprising prodigiosin isolated from Serratia marcescence B-1231 KCTC 0386BP, as an effective ingredient. The prodigiosin is immunosup-pressive by selectively suppressing the proliferation of T-cells through the suppression of the expression of IL-2 receptors, which is needed for the activation of T-cells. Prodigiosin can be used either alone or in conjunction with cyclosporin A for greater effect, since the two substances have different mode of actions. These make prodigiosin effective for the prevention and treatment of acute graft-versus-host disease. |
| priorityDate |
2005-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |